EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The feasibility and acceptability of collecting psychosocial outcome measures embedded within a precision medicine trial for childhood cancer

Eden G Robertson iD, Kate Hetherington, Rebecca Daly iD, Mark W Donoghoe, Nicholas Handelsman, David S Ziegler, Claire E Wakefield

Cancer Medicine · 2024

DOI: 10.1002/cam4.7339 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Eden G Robertson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Discipline of Paediatrics and Child Health, School of Clinical Medicine, UNSW Medicine & Health, UNSW Sydney, Kensington, New South Wales, Australia. Hauptthemen laut MEDLINE: Precision Medicine, Neoplasms, Feasibility Studies, Parents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kids with Cancer Foundation Australia, National Health and Medical Research Council, Cancer Institute NSW.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patient‐reported outcomes measures (PROMs) are increasingly being collected within cancer clinical trials, yet limited literature on the feasibility and acceptability of doing so.

Methods

We collected parent‐proxy and adolescent (≥12 years old) PROMs through a longitudinal, psychosocial sub‐study (‘PRISM‐Impact’) embedded in a precision medicine trial for children with poor prognosis cancer (‘PRISM’). We report on feasibility (response, participation, and attrition rates; follow‐up and responding to elevated distress) and acceptability (parents’ perceived benefit/burden of participation; and impact on decision to participate in PRISM) of PRISM‐Impact.

Results

Over the reporting period, 462 families were eligible for PRISM‐Impact. Family and adolescent response rates were 53% and 45%, respectively. Parents whose child had relapsed were more likely to participate in PRISM‐Impact than parents whose child had not ( p < 0.001). Parent and adolescent attrition rates were 30% and 56% respectively. We conducted 478 calls for intake and to follow‐up on missing questionnaires, and 122 calls to respond to elevated distress. Parents reported wanting to participate in PRISM‐Impact for altruistic reasons and because they valued psychosocial research. Parents reported little‐to‐no burden and some benefit from participating in PRISM‐Impact, with little change in ratings overtime. Most parents felt that participating in PRISM‐Impact did not impact their desire to participate in PRISM (72%), with some feeling more eager to participate (19%).

Conclusions

PRISM‐Impact response rates were comparable to other psycho‐oncology studies, despite the poor prognosis population. Integration of PROMs within a paediatric oncology trial is acceptable to parents, and may provide a more comprehensive assessment of the impact of trial participation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precision MedicineNeoplasmsFeasibility StudiesParentsPatient Reported Outcome MeasuresHumansFemaleMaleAdolescentChildSurveys and QuestionnairesLongitudinal StudiesQuality of LifeAdult

Stichwörter der Autor:innen

acceptabilityclinical trialfeasibilityoncologyoutcome measurespaediatricpsychosocial

Autor:innen und Institutionen

  • Discipline of Paediatrics and Child Health, School of Clinical Medicine, UNSW Medicine & Health, UNSW Sydney, Kensington, New South Wales, Australia.
  • Behavioural Sciences Unit, Kids Cancer Centre, Sydney Children's Hospital, Sydney, New South Wales, Australia.
  • Kids Cancer Centre, Sydney Children's Hospital, Sydney, New South Wales, Australia.
  • Stats Central, Mark Wainwright Analytical Centre, UNSW Sydney, Kensington, New South Wales, Australia.
  • Children's Cancer Institute, UNSW Sydney, Sydney, New South Wales, Australia.

ORCID-Profile: Eden G Robertson, Rebecca Daly

Förderung

  • Kids with Cancer Foundation Australia
  • National Health and Medical Research Council
  • Cancer Institute NSW
  • Luminesce Alliance - Innovation for Children's Health

Zitieren

APA

Robertson, E. G., Hetherington, K., Daly, R., Donoghoe, M. W., Handelsman, N., Ziegler, D. S., & Wakefield, C. E. (2024). The feasibility and acceptability of collecting psychosocial outcome measures embedded within a precision medicine trial for childhood cancer. Cancer Medicine. https://doi.org/10.1002/cam4.7339

Vancouver

Robertson EG, Hetherington K, Daly R, Donoghoe MW, Handelsman N, Ziegler DS, et al. The feasibility and acceptability of collecting psychosocial outcome measures embedded within a precision medicine trial for childhood cancer. Cancer Medicine. 2024. doi:10.1002/cam4.7339

BibTeX
@article{Robertson2024,
  author = {Robertson, Eden G and Hetherington, Kate and Daly, Rebecca and Donoghoe, Mark W and Handelsman, Nicholas and Ziegler, David S and Wakefield, Claire E},
  title = {The feasibility and acceptability of collecting psychosocial outcome measures embedded within a precision medicine trial for childhood cancer},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.7339}
}
Kostenlos starten →